Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Estrella Immunopharma, Inc. - Common Stock (NQ:ESLA)

1.090 +1.090 (+1089900.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,172
Open 0.0001
Bid (Size) 1.080 (300)
Ask (Size) 1.140 (1,600)
Prev. Close 0.0001
Today's Range 1.070 - 1.122
52wk Range 0.7800 - 3.150
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Estrella Immunopharma to Participate in the D. Boral Capital Global Conference
From Estrella Immunopharma, Inc.
Via Business Wire
Which stocks are moving on Monday? ↗
Via Chartmill

Performance

YTD
-21.6%
-21.6%
1 Month
-33.5%
-33.5%
3 Month
-4.4%
-4.4%
6 Month
-39.4%
-39.4%
1 Year
+8.0%
+8.0%

More News

Read More
News headline image
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research
From Estrella Immunopharma, Inc.
Via Business Wire
Monday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
From Estrella Immunopharma, Inc.
Via Business Wire
Curious about the stocks that are showing activity after the closing bell on Friday? ↗
Via Chartmill
Here are the top movers in Thursday's session. ↗
Via Chartmill
Thursday's session: top gainers and losers ↗
Via Chartmill
News headline image
Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
From Estrella Immunopharma, Inc.
Via Business Wire
BioMedNewsBreaks – Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) Closes $8.0 Million Registered Direct Offering
Via Investor Brand Network
News headline image
Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement
From Estrella Immunopharma, Inc.
Via Business Wire
News headline image
Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
From Estrella Immunopharma, Inc.
Via Business Wire
News headline image
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation
From Estrella Immunopharma, Inc.
Via Business Wire
News headline image
Tuesday's session: top gainers and losers ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Via Benzinga
News headline image
Which stocks are moving on Monday? ↗
Via Chartmill
News headline image
Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients
From Estrella Immunopharma, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Via Benzinga
News headline image
Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements
From Estrella Immunopharma, Inc.
Via Business Wire
News headline image
Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
From Estrella Immunopharma, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing
From Estrella Immunopharma, Inc.
Via Business Wire
News headline image
Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin’s Lymphomas
From Estrella Immunopharma, Inc.
Via Business Wire
News headline image
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners
From Estrella Immunopharma, Inc.
Via Business Wire

Frequently Asked Questions

Is Estrella Immunopharma, Inc. - Common Stock publicly traded?
Yes, Estrella Immunopharma, Inc. - Common Stock is publicly traded.
What exchange does Estrella Immunopharma, Inc. - Common Stock trade on?
Estrella Immunopharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Estrella Immunopharma, Inc. - Common Stock?
The ticker symbol for Estrella Immunopharma, Inc. - Common Stock is ESLA on the Nasdaq Stock Market
What is the current price of Estrella Immunopharma, Inc. - Common Stock?
The current price of Estrella Immunopharma, Inc. - Common Stock is 1.090
When was Estrella Immunopharma, Inc. - Common Stock last traded?
The last trade of Estrella Immunopharma, Inc. - Common Stock was at 05/29/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.